| Document |
Document Title |
|
WO/2008/129288 |
There is provided compounds of formula (I), wherein Y1, Y2, Y3, Y4, T1, T2, W1, W2, R1 and R2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases ...
|
|
WO/2008/131047 |
The invention relates to plasminogen activator- 1 (PAl-1I) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such c...
|
|
WO/2008/131047 |
The invention relates to plasminogen activator- 1 (PAl-1I) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such c...
|
|
WO/2008/131219 |
Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema asso...
|
|
WO/2008/126731 |
The invention relates to novel aryl derivatives which have excellent blood sugar lowering effect and are effective in treating diseases of glycometabolism and lipid metabolism, or diseases in which peroxisome proliferator activated recep...
|
|
WO/2008/125296 |
The present invention relates to novel vanilloid receptor ligands, methods for the production thereof, pharmaceuticals containing these compounds, and the use of these compounds for the production of pharmaceuticals.
|
|
WO/2008/122115 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable ...
|
|
WO/2008/124524 |
Certain aryl sulfonamide compounds are CCK2 receptor modulators useful in the treatment of CCK2 receptor-mediated diseases.
|
|
WO/2008/124524 |
Certain aryl sulfonamide compounds are CCK2 receptor modulators useful in the treatment of CCK2 receptor-mediated diseases.
|
|
WO/2008/123207 |
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic neuropathy. [MEANS FOR SOLVING PROBLEMS] Disclosed is an ornithine derivative having an EP4 receptor antagonistic activity. In the compo...
|
|
WO/2008/121877 |
The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administerin...
|
|
WO/2008/119772 |
The invention provides compounds of the formula (I). N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein W is H, C1-C6alkyl, C3-C6cycloalkyl, aryl or heterocyclyl...
|
|
WO/2008/119773 |
The invention provides compounds of the formula (I). N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein W is H,C 1-C 6 alkyl, C 3-C 6 cycloalkyl, aryl or heteroc...
|
|
WO/2008/113756 |
The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having Formula (I) below wherein R, R 1, R 2, R 3, R 4, R 5, n and m have the meanings reported in the specification; th...
|
|
WO/2008/113760 |
The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R denotes a group of formula (A) wherein X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof ...
|
|
WO/2008/114022 |
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as "BPSAAA compounds"), as described herein, and in...
|
|
WO/2008/113760 |
The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R denotes a group of formula (A) wherein X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof ...
|
|
WO/2008/114831 |
Disclosed is an antibacterial agent or the like, which contains a compound having excellent antibacterial activity against drug-resistant bacteria such as MRSA and VRE. The compound has a simple structure and can be easily produced comme...
|
|
WO/2008/113756 |
The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having Formula (I) below wherein R, R 1, R 2, R 3, R 4, R 5, n and m have the meanings reported in the specification; th...
|
|
WO/2008/110698 |
The invention relates to a method for preparing polyfluorinated sulphanylamides of formula (I) and polyfluorinated sulphinamidines of formula (II), wherein R1-R4 are defined as in the claims, and for preparing the precursors of same.
|
|
WO/2008/109991 |
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...
|
|
WO/2008/110698 |
The invention relates to a method for preparing polyfluorinated sulphanylamides of formula (I) and polyfluorinated sulphinamidines of formula (II), wherein R1-R4 are defined as in the claims, and for preparing the precursors of same.
|
|
WO/2008/107661 |
There is provided compounds of formula (I), wherein Rx, Ry, X1, X2, L1, L2, Y1 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which...
|
|
WO/2008/107176 |
The invention relates to meta-substituted phenyl sulfonyl amides of secondary amino acid amides according to the general formula (I), (II), or (III), the production thereof, and the use thereof as matriptase inhibitors, in particular the...
|
|
WO/2008/105386 |
Disclosed is a compound represented by the general formula shown below, which can bind to a retinoid X receptor (RXR) (which is one of nuclear receptors) to exhibit an agonistic or antagonistic activity on the receptor. wherein R1 is sel...
|
|
WO/2008/101810 |
The present invention relates to washing and cleaning compositions comprising urea derivatives and to the use of these washing and cleaning compositions for cleaning of textiles and surfaces.
|
|
WO/2008/102908 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...
|
|
WO/2008/099727 |
Disclosed is a novel α-substituted acrylate derivative which is useful as a material for a polymer compound for photoresist compositions which is excellent in control of dissolution rate, while maintaining high transparency around 193 n...
|
|
WO/2008/098244 |
The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides f...
|
|
WO/2008/093767 |
Disclosed are: a benzylamine derivative typified by the formula below and a pharmaceutically acceptable acid addition salt thereof; a pharmaceutical agent comprising the derivative or the pharmaceutically acceptable acid addition salt th...
|
|
WO/2008/088727 |
This invention relates to novel endothelin receptor antagonists of the formula (I), derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of...
|
|
WO/2008/088727 |
This invention relates to novel endothelin receptor antagonists of the formula (I), derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of...
|
|
WO/2008/083729 |
The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging.
|
|
WO/2008/078200 |
The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R2 may be, for example, 2-pyridyl-CH2-, 3- pyridyl-CH2-, 4-pyridyl-CH2-, a sulfonyl group as de...
|
|
WO/2008/074755 |
This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are respons...
|
|
WO/2008/074755 |
This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are respons...
|
|
WO/2008/077070 |
Described herein are methods for rational design of inhibitors of HIV-1 protease, and crystal structures of HIV-1 protease inhibitors bound to HIV-1 protease.
|
|
WO/2008/077070 |
Described herein are methods for rational design of inhibitors of HIV-1 protease, and crystal structures of HIV-1 protease inhibitors bound to HIV-1 protease.
|
|
WO/2008/075353 |
The present invention relates to sulfonamide derivatives of formula (I) (wherein R1, R2, R3, R3', R4and R5are as defined in the claims), to pharmaceutical compositions comprising the same, and to uses thereof. Compounds of the invention ...
|
|
WO/2008/074132 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
|
WO/2008/073789 |
The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
|
|
WO/2008/071421 |
Nitroderivatives of carbonic anhydrase inhibitors having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration...
|
|
WO/2008/071398 |
The present invention relates to the use of a sulfonamide compound of formula (I): wherein R1 is selected from the group consisting of H, CN, halogen, trifluoromethyl, methyl, ethyl, hydroxy, methoxy, ethoxy, morpholino, R2 is selected f...
|
|
WO/2008/068170 |
The use of compounds of the formula (I): Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(=Y)-R2 where Y is selected from O or S; R1 is H, a salt or readily hydrolysable substituent; R2 is selected from H or CH3, CH2F, CF2H or CF3; R3 and R4 are selected ...
|
|
WO/2008/064595 |
5-[(2R)-[2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]
propyl]-2-methoxybenzenesulfonamide, a pharmaceutical composition containing the compound, and the synthesis method thereof. The compound has strong antagonism toward α1-adren...
|
|
WO/2008/059800 |
The invention aims at providing compounds which have sufficiently high affinity for NMDA receptor and can inhibit the inflow of calcium ions efficiently and which have low cytotoxicity and low molecular weights and can be expected to exh...
|
|
WO/2008/061006 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof, which are modulators of secreted frizzled related protein- 1, are disclosed. The compounds, and compositions containing the compounds, can be used to treat various d...
|
|
WO/2008/059335 |
Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described her...
|
|
WO/2008/050168 |
The present invention relates to new sulfonamide derivatives of formula (I), wherein R1 -R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective ...
|
|
WO/2008/050125 |
There is provided a compound of formula (I) wherein R1a, R2a, R3, X1 to X6, a, b and c have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, inhibitors of HDAC enzyme activity, and thus, in ...
|
